drugset / Trial / NCT07000292
MSC303 Subcutaneous Injection for the Treatment of Immunologic Glomerular Disease.
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of MSC303 in patients with Immune glomerular diseases.
Timeline
- Start
- 2025-06-20
- Primary completion
- 2026-05-20
- Completion
- 2027-02-20